REPORT ID 15418

EMEA (Europe, Middle East and Africa) PDE Inhibitors Market Report 2017

Publish Date
29-Nov-17
Pages
105
Format
Electronic (PDF)

In this report, the EMEA PDE Inhibitors market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (), revenue (Million USD), market share and growth rate of PDE Inhibitors for these regions, from 2012 to 2022 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA PDE Inhibitors market competition by top manufacturers/players, with PDE Inhibitors sales volume (), price (), revenue (Million USD) and market share for each manufacturer/player; the top players including
    Hanmi Science Holding
    Boehringer Ingelheim
    Takeda Pharmaceuticals
    Pfizer
    Omeros
    Anacor Pharmaceuticals
    Otsuka
    Chiesi Farmaceutici
    Verona Pharma
    NuSirt Biopharma

On the basis of product, this report displays the sales volume (), revenue (Million USD), product price (), market share and growth rate of each type, primarily split into
    PDE5
    PDE4
    Viagra
    Cialis
    Levitra
    Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (), market share and growth rate of PDE Inhibitors for each application, including
    GENITOURINARY
    CARDIOVASCULAR DISEASES
    NEUROLOGICAL DISEASES
    DERMATOLOGICAL DISORDERS
    RESPIRATORY DISEASES
    OTHER INDICATIONS

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) PDE Inhibitors Market Report 2017
1 PDE Inhibitors Overview
    1.1 Product Overview and Scope of PDE Inhibitors
    1.2 Classification of PDE Inhibitors
        1.2.1 EMEA PDE Inhibitors Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 EMEA PDE Inhibitors Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 PDE5
        1.2.4 PDE4
        1.2.5 Viagra
        1.2.6 Cialis
        1.2.7 Levitra
        1.2.8 Others
    1.3 EMEA PDE Inhibitors Market by Application/End Users
        1.3.1 EMEA PDE Inhibitors Sales (Volume) and Market Share Comparison by Application (2012-2022
        1.3.2 GENITOURINARY
        1.3.3 CARDIOVASCULAR DISEASES
        1.3.4 NEUROLOGICAL DISEASES
        1.3.5 DERMATOLOGICAL DISORDERS
        1.3.6 RESPIRATORY DISEASES
        1.3.7 OTHER INDICATIONS
    1.4 EMEA PDE Inhibitors Market by Region
        1.4.1 EMEA PDE Inhibitors Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 Europe Status and Prospect (2012-2022)
        1.4.3 Middle East Status and Prospect (2012-2022)
        1.4.4 Africa Status and Prospect (2012-2022)
    1.5 EMEA Market Size (Value and Volume) of PDE Inhibitors (2012-2022)
        1.5.1 EMEA PDE Inhibitors Sales and Growth Rate (2012-2022)
        1.5.2 EMEA PDE Inhibitors Revenue and Growth Rate (2012-2022)

2 EMEA PDE Inhibitors Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA PDE Inhibitors Market Competition by Players/Manufacturers
        2.1.1 EMEA PDE Inhibitors Sales Volume and Market Share of Major Players (2012-2017)
        2.1.2 EMEA PDE Inhibitors Revenue and Share by Players (2012-2017)
        2.1.3 EMEA PDE Inhibitors Sale Price by Players (2012-2017)
    2.2 EMEA PDE Inhibitors (Volume and Value) by Type/Product Category
        2.2.1 EMEA PDE Inhibitors Sales and Market Share by Type (2012-2017)
        2.2.2 EMEA PDE Inhibitors Revenue and Market Share by Type (2012-2017)
        2.2.3 EMEA PDE Inhibitors Sale Price by Type (2012-2017)
    2.3 EMEA PDE Inhibitors (Volume) by Application
    2.4 EMEA PDE Inhibitors (Volume and Value) by Region
        2.4.1 EMEA PDE Inhibitors Sales and Market Share by Region (2012-2017)
        2.4.2 EMEA PDE Inhibitors Revenue and Market Share by Region (2012-2017)
        2.4.3 EMEA PDE Inhibitors Sales Price by Region (2012-2017)

3 Europe PDE Inhibitors (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe PDE Inhibitors Sales and Value (2012-2017)
        3.1.1 Europe PDE Inhibitors Sales Volume and Growth Rate (2012-2017)
        3.1.2 Europe PDE Inhibitors Revenue and Growth Rate (2012-2017)
    3.2 Europe PDE Inhibitors Sales and Market Share by Type
    3.3 Europe PDE Inhibitors Sales and Market Share by Application
    3.4 Europe PDE Inhibitors Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe PDE Inhibitors Sales Volume by Countries (2012-2017)
        3.4.2 Europe PDE Inhibitors Revenue by Countries (2012-2017)
        3.4.3 Germany PDE Inhibitors Sales and Growth Rate (2012-2017)
        3.4.4 France PDE Inhibitors Sales and Growth Rate (2012-2017)
        3.4.5 UK PDE Inhibitors Sales and Growth Rate (2012-2017)
        3.4.6 Russia PDE Inhibitors Sales and Growth Rate (2012-2017)
        3.4.7 Italy PDE Inhibitors Sales and Growth Rate (2012-2017)
        3.4.8 Benelux PDE Inhibitors Sales and Growth Rate (2012-2017)

4 Middle East PDE Inhibitors (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East PDE Inhibitors Sales and Value (2012-2017)
        4.1.1 Middle East PDE Inhibitors Sales Volume and Growth Rate (2012-2017)
        4.1.2 Middle East PDE Inhibitors Revenue and Growth Rate (2012-2017)
    4.2 Middle East PDE Inhibitors Sales and Market Share by Type
    4.3 Middle East PDE Inhibitors Sales and Market Share by Application
    4.4 Middle East PDE Inhibitors Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East PDE Inhibitors Sales Volume by Countries (2012-2017)
        4.4.2 Middle East PDE Inhibitors Revenue by Countries (2012-2017)
        4.4.3 Saudi Arabia PDE Inhibitors Sales and Growth Rate (2012-2017)
        4.4.4 Israel PDE Inhibitors Sales and Growth Rate (2012-2017)
        4.4.5 UAE PDE Inhibitors Sales and Growth Rate (2012-2017)
        4.4.6 Iran PDE Inhibitors Sales and Growth Rate (2012-2017)

5 Africa PDE Inhibitors (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa PDE Inhibitors Sales and Value (2012-2017)
        5.1.1 Africa PDE Inhibitors Sales Volume and Growth Rate (2012-2017)
        5.1.2 Africa PDE Inhibitors Revenue and Growth Rate (2012-2017)
    5.2 Africa PDE Inhibitors Sales and Market Share by Type
    5.3 Africa PDE Inhibitors Sales and Market Share by Application
    5.4 Africa PDE Inhibitors Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa PDE Inhibitors Sales Volume by Countries (2012-2017)
        5.4.2 Africa PDE Inhibitors Revenue by Countries (2012-2017)
        5.4.3 South Africa PDE Inhibitors Sales and Growth Rate (2012-2017)
        5.4.4 Nigeria PDE Inhibitors Sales and Growth Rate (2012-2017)
        5.4.5 Egypt PDE Inhibitors Sales and Growth Rate (2012-2017)
        5.4.6 Algeria PDE Inhibitors Sales and Growth Rate (2012-2017)

6 EMEA PDE Inhibitors Manufacturers/Players Profiles and Sales Data
    6.1 Hanmi Science Holding
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 PDE Inhibitors Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Hanmi Science Holding PDE Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Boehringer Ingelheim
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 PDE Inhibitors Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Boehringer Ingelheim PDE Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Takeda Pharmaceuticals
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 PDE Inhibitors Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Takeda Pharmaceuticals PDE Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Pfizer
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 PDE Inhibitors Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Pfizer PDE Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Omeros
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 PDE Inhibitors Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Omeros PDE Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Anacor Pharmaceuticals
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 PDE Inhibitors Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Anacor Pharmaceuticals PDE Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Otsuka
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 PDE Inhibitors Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Otsuka PDE Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Chiesi Farmaceutici
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 PDE Inhibitors Product Type, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Chiesi Farmaceutici PDE Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Verona Pharma
        6.9.1 Company Basic Information, Manufacturing Base and Competitors
        6.9.2 PDE Inhibitors Product Type, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Verona Pharma PDE Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 NuSirt Biopharma
        6.10.1 Company Basic Information, Manufacturing Base and Competitors
        6.10.2 PDE Inhibitors Product Type, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 NuSirt Biopharma PDE Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview

7 PDE Inhibitors Manufacturing Cost Analysis
    7.1 PDE Inhibitors Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of PDE Inhibitors

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 PDE Inhibitors Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of PDE Inhibitors Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA PDE Inhibitors Market Forecast (2017-2022)
    11.1 EMEA PDE Inhibitors Sales, Revenue and Price Forecast (2017-2022)
        11.1.1 EMEA PDE Inhibitors Sales and Growth Rate Forecast (2017-2022)
        11.1.2 EMEA PDE Inhibitors Revenue and Growth Rate Forecast (2017-2022)
        11.1.3 EMEA PDE Inhibitors Price and Trend Forecast (2017-2022)
    11.2 EMEA PDE Inhibitors Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.3 Europe PDE Inhibitors Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.4 Middle Eastt PDE Inhibitors Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.5 Africa PDE Inhibitors Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.6 EMEA PDE Inhibitors Sales Forecast by Type (2017-2022)
    11.7 EMEA PDE Inhibitors Sales Forecast by Application (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer